Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Shanna Arnold Egloff, Xiting Cao, Rebecca Lachs, Casey Martin, Meredith Mattlin, Emma Fennell, Dillan Rayburn, Daniel Schlauch, Dax Kurbegov, Susan Ide & Minoo Battiwalla. (2023) Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices. Leukemia & Lymphoma 0:0, pages 1-12.
Read now
Read now
Jonathan Feld, Abigail Belasen & Shyamala C Navada. (2020) Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. Expert Review of Anticancer Therapy 20:6, pages 465-482.
Read now
Read now
Georgina S. Daher-Reyes, Brayan M. Merchan & Karen W. L. Yee. (2019) Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Expert Opinion on Investigational Drugs 28:10, pages 835-849.
Read now
Read now
Natalie Uy, Abhay Singh, Steven D. Gore & Thomas Prebet. (2017) Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opinion on Pharmacotherapy 18:12, pages 1213-1224.
Read now
Read now
Jonathan Canaani & Arnon Nagler. (2016) Established and emerging targeted therapies in the myelodysplastic syndromes. Expert Review of Hematology 9:10, pages 997-1005.
Read now
Read now
Shyamala C. Navada & Lewis R. Silverman. (2016) The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy 16:8, pages 805-810.
Read now
Read now
Abdallah Abou Zahr, Carolina Bernabe Ramirez, Jocelyn Wozney, Thomas Prebet & Amer M. Zeidan. (2016) New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Expert Review of Hematology 9:4, pages 377-388.
Read now
Read now
Christopher R Cogle, Jesse D Ortendahl, Tanya GK Bentley, Ayanna M Anene, Scott Megaffin, Thomas J McKearn, Michael E Petrone & Sudipto Mukherjee. (2016) Cost–effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 275-284.
Read now
Read now
Abdallah Abou Zahr, Ehab Saad Aldin, Lisa Barbarotta, Nikolai Podoltsev & Amer M Zeidan. (2015) The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes. Expert Review of Anticancer Therapy 15:9, pages 1019-1036.
Read now
Read now
Vu H. Duong, Bhavana Bhatnagar, Dan P. Zandberg, Emily J. Vannorsdall, Michael L. Tidwell, Qing Chen & Maria R. Baer. (2015) Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leukemia & Lymphoma 56:6, pages 1718-1722.
Read now
Read now
Drorit G Merkel & Arnon Nagler. (2013) The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm. Expert Review of Hematology 6:6, pages 665-676.
Read now
Read now
Jeffrey Bryan, Hagop Kantarjian, Guillermo Garcia-Manero & Elias Jabbour. (2011) Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 661-672.
Read now
Read now
Jacqueline S Garcia, Nitin Jain & Lucy A Godley. (2010) An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes. OncoTargets and Therapy 3, pages 1-13.
Read now
Read now
Steven E McCormack & Erica D Warlick. (2010) Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine. OncoTargets and Therapy 3, pages 157-165.
Read now
Read now
Marcelo Iastrebner, Jun Ho Jang, Elsa Nucifora, Kihyun Kim, Federico Sackmann, Dong Hwan Kim, Sergio Orlando, Chul Won Jung, Ana Basquiera, Graciela Klein, Fernando Santini, Haydee I. Bernard, Jorge Korin & Gustavo Taborda. (2010) Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience. Leukemia & Lymphoma 51:12, pages 2250-2257.
Read now
Read now
Naomi Galili & Azra Raza. (2010) Pharmacotherapy of myelodysplastic syndromes. Expert Opinion on Pharmacotherapy 11:11, pages 1889-1899.
Read now
Read now
Fabio PS Santos, Hagop Kantarjian, Guillermo Garcia-Manero, Jean-Pierre Issa & Farhad Ravandi. (2010) Decitabine in the treatment of myelodysplastic syndromes. Expert Review of Anticancer Therapy 10:1, pages 9-22.
Read now
Read now
Articles from other publishers (72)
Majjid A. Qaria, Chunyan Xu, Ran Hu, Roua A. Alsubki, Mohamed Yassin Ali, Sethupathy Sivasamy, Kotb A. Attia & Daochen Zhu. (2023) Ectoine Globally Hypomethylates DNA in Skin Cells and Suppresses Cancer Proliferation. Marine Drugs 21:12, pages 621.
Crossref
Crossref
Kristína Šimoničová, Lubos Janotka, Helena Kavcova, Zdena Sulova, Lucia Messingerova & Albert Breier. (2023) Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol. Cancers 15:11, pages 3063.
Crossref
Crossref
Hussein Awada, Carmelo Gurnari, Zhuoer Xie, Jan Philipp Bewersdorf & Amer M. Zeidan. (2023) What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 15:8, pages 2248.
Crossref
Crossref
Inkyung Jung, Jungeun An & Myunggon Ko. (2023) Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy. Biomedicines 11:3, pages 654.
Crossref
Crossref
Tomoyuki Saga, Michiyo Kanagawa, Tomoya Harada, Lang Lang, Fumihiko Yamawaki & Toshimichi Ishihara. (2023) Prognostic Value of Pretreatment Fetal Hemoglobin Levels in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia Treated with Azacitidine: A Single-center Retrospective Study. Internal Medicine.
Crossref
Crossref
Alicja Pawlak, Kinga Chybicka, Ewa Zioło, Leon Strządała & Wojciech Kałas. (2022) The Contrasting Delayed Effects of Transient Exposure of Colorectal Cancer Cells to Decitabine or Azacitidine. Cancers 14:6, pages 1530.
Crossref
Crossref
Kristína Šimoničová, Ľuboš Janotka, Helena Kavcová, Zdena Sulová, Albert Breier & Lucia Messingerova. (2022) Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Drug Resistance Updates 61, pages 100805.
Crossref
Crossref
Sridhar A Malkaram, Aymen Shatnawi, Jun Fan, Hetty Carraway, James Denvir, Donald A Primerano, Zakaria Y Abd Elmageed & Tamer E Fandy. (2022) Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents. Cancer Control 29, pages 107327482210740.
Crossref
Crossref
Eric Huselton, Michael P. Rettig, Kirsten Campbell, Amanda F. Cashen, John F. DiPersio, Feng Gao, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Mark A. Schroeder, Geoffrey L. Uy, Stephen Marcus & Peter Westervelt. (2021) Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research 110, pages 106713.
Crossref
Crossref
Guangjie Zhao, Qian Wang, Shuang Li & Xiaoqin Wang. (2021) Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism. Frontiers in Oncology 11.
Crossref
Crossref
Julia Stomper, John Charles Rotondo, Gabriele Greve & Michael Lübbert. (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35:7, pages 1873-1889.
Crossref
Crossref
Jan Philipp Bewersdorf & Amer M. Zeidan. (2021) Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best Practice & Research Clinical Haematology 34:1, pages 101245.
Crossref
Crossref
Ľuboš Janotka, Lucia Messingerová, Kristína Šimoničová, Helena Kavcová, Katarína Elefantová, Zdena Sulová & Albert Breier. (2021) Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents. International Journal of Molecular Sciences 22:4, pages 2076.
Crossref
Crossref
Abigail Belasen & Shyamala C. Navada. (2020) Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure. EMJ Hematology, pages 52-64.
Crossref
Crossref
Bryan C. Hambley & Amy E. DeZern. 2020. Diagnosis and Management of Myelodysplastic Syndromes. Diagnosis and Management of Myelodysplastic Syndromes
147
163
.
Valeria Santini. (2019) How I treat MDS after hypomethylating agent failure. Blood 133:6, pages 521-529.
Crossref
Crossref
Takahiro Sato, Jean-Pierre J. Issa & Patricia Kropf. (2017) DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor Perspectives in Medicine 7:5, pages a026948.
Crossref
Crossref
Susmitha Apuri, Najla Al Ali, Eric Padron, Jeffrey E. Lancet, Alan F. List & Rami S. Komrokji. (2017) Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clinical Lymphoma Myeloma and Leukemia 17:4, pages 211-214.
Crossref
Crossref
Hetty E. Carraway. (2016) Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure. Hematology 2016:1, pages 470-477.
Crossref
Crossref
Jeannine Diesch, Anabel Zwick, Anne-Kathrin Garz, Anna Palau, Marcus Buschbeck & Katharina S. Götze. (2016) A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clinical Epigenetics 8:1.
Crossref
Crossref
Rami S. Komrokji. (2016) Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book:36, pages e345-e352.
Crossref
Crossref
BAOQIANG WU, YONG JIANG, FENG ZHU, DONGLIN SUN & HONGJUN HUANG. (2016) Demethylation effects of elemene on the GSTP1 gene in HCC cell line QGY7703. Oncology Letters 11:4, pages 2545-2551.
Crossref
Crossref
Christopher R. Cogle, Bart L. Scott, Thomas Boyd & Guillermo Garcia-Manero. (2015) Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. The Oncologist 20:12, pages 1404-1412.
Crossref
Crossref
Daniel A. Roberts & David P. Steensma. (2015) Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Current Hematologic Malignancy Reports 10:3, pages 318-328.
Crossref
Crossref
Christopher R. Cogle. (2015) Incidence and Burden of the Myelodysplastic Syndromes. Current Hematologic Malignancy Reports 10:3, pages 272-281.
Crossref
Crossref
Christopher A. Hamm & Fabricio F. Costa. (2015) Epigenomes as therapeutic targets. Pharmacology & Therapeutics 151, pages 72-86.
Crossref
Crossref
Rami S. Komrokji. (2015) Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents. Clinical Lymphoma Myeloma and Leukemia 15, pages S56-S59.
Crossref
Crossref
Stéphanie Harel, Amina Cherait, Céline Berthon, Christophe Willekens, Sophie Park, Marthe Rigal, Sabine Brechignac, Sylvain Thépot, Bruno Quesnel, Claude Gardin, Lionel Adès, Pierre Fenaux & Thorsten Braun. (2015) Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research 39:5, pages 501-504.
Crossref
Crossref
Paolo Strati, Hagop Kantarjian, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naval Daver, Tapan Kadia, Zeev Estrov, Guillermo Garcia-Manero, Marina Konopleva, Trivikram Rajkhowa, Menda Durand, Michael Andreeff, Mark Levis & Jorge Cortes. (2015) Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. American Journal of Hematology 90:4, pages 276-281.
Crossref
Crossref
Elias J. Jabbour, Guillermo Garcia‐Manero, Paolo Strati, Asmita Mishra, Najla H. Al Ali, Eric Padron, Jeffrey Lancet, Tapan Kadia, Naval Daver, Susan O'Brien, David P. Steensma, Mikkael A. Sekeres, Steven D. Gore, Amy Dezern, Gail J. Roboz, Alan F. List, Hagop M. Kantarjian & Rami S. Komrokji. (2014) Outcome of patients with low‐risk and intermediate‐1‐risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium. Cancer 121:6, pages 876-882.
Crossref
Crossref
Valeria Santini, Thomas Prebet, Pierre Fenaux, Norbert Gattermann, Lars Nilsson, Michael Pfeilstöcker, Paresh Vyas & Alan F. List. (2014) Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research 38:12, pages 1381-1391.
Crossref
Crossref
Daniel A. Pollyea & Jonathan A. Gutman. (2014) Stopping Higher-Risk Myelodysplastic Syndrome in Its Tracks. Current Hematologic Malignancy Reports 9:4, pages 421-431.
Crossref
Crossref
Guillermo Montalbán Bravo, Elinor Lee, Bryan Merchan, Hagop M. Kantarjian & Guillermo García-Manero. (2014) Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution. British Journal of Haematology 166:5, pages 646-659.
Crossref
Crossref
Amer M. Zeidan, Mohamed A. Kharfan-Dabaja & Rami S. Komrokji. (2014) Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Current Opinion in Hematology 21:2, pages 123-130.
Crossref
Crossref
Björn Hackanson & Michael Daskalakis. 2014. Small Molecules in Oncology. Small Molecules in Oncology
269
297
.
Elizabeth Griffiths, Richard L. Momparler & Adam R. Karpf. 2014. Epigenetic Therapy of Cancer. Epigenetic Therapy of Cancer
171
188
.
Michael Daskalakis, Tina E. Joeckel, Michael Lübbert & A. Kuendgen. 2014. Epigenetic Therapy of Cancer. Epigenetic Therapy of Cancer
145
170
.
Yogen Saunthararajah. (2013) Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology 2013:1, pages 511-521.
Crossref
Crossref
Metin Karahoca & Richard L Momparler. (2013) Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clinical Epigenetics 5:1.
Crossref
Crossref
Vu H. Duong, Karen Lin, Tea Reljic, Ambuj Kumar, Najla H. Al Ali, Jeffrey E. Lancet, Alan F. List & Rami S. Komrokji. (2013) Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure. Clinical Lymphoma Myeloma and Leukemia 13:6, pages 711-715.
Crossref
Crossref
Gerald S. Falchook, Siqing Fu, Aung Naing, David S. Hong, Wei Hu, Stacy Moulder, Jennifer J. Wheler, Anil K. Sood, Ernesto Bustinza-Linares, Kristin L. Parkhurst & Razelle Kurzrock. (2013) Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Investigational New Drugs 31:5, pages 1192-1200.
Crossref
Crossref
Monique P. Curran. (2013) Decitabine: A Review of its Use in Older Patients with Acute Myeloid Leukaemia. Drugs & Aging 30:6, pages 447-458.
Crossref
Crossref
Ellen J.B. Derissen, Jos H. Beijnen & Jan H.M. Schellens. (2013) Concise Drug Review: Azacitidine and Decitabine. The Oncologist 18:5, pages 619-624.
Crossref
Crossref
Yun‐Gyoo Lee, Inho Kim, Sung‐Soo Yoon, Seonyang Park, June Won Cheong, Yoo Hong Min, Jeong‐Ok Lee, Soo‐Mee Bang, Hyeon Gyu Yi, Chul Soo Kim, Yong Park, Byung‐Soo Kim, Yeung‐Chul Mun, Chu‐Myoung Seong, Jinny Park, Jae Hoon Lee, Sung‐Yong Kim, Hong Ghi Lee, Yeo‐Kyeoung Kim & Hyeoung‐Joon Kim. (2013) Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. British Journal of Haematology 161:3, pages 339-347.
Crossref
Crossref
H. Joachim Deeg, David T. Bowen, Steven D. Gore, Torsten Haferlach, Michelle M. Le Beau & Charlotte NiemeyerAmer M. Zeidan & Steven D. Gore. 2013. Myelodysplastic Syndromes. Myelodysplastic Syndromes
189
210
.
Carole Seidel, Cristina Florean, Michael Schnekenburger, Mario Dicato & Marc Diederich. (2012) Chromatin-modifying agents in anti-cancer therapy. Biochimie 94:11, pages 2264-2279.
Crossref
Crossref
Tina E. Joeckel & Michael Lübbert. (2012) Clinical Results With the DNA Hypomethylating Agent 5-Aza-2′-Deoxycytidine (Decitabine) in Patients With Myelodysplastic Syndromes: An Update. Seminars in Hematology 49:4, pages 330-341.
Crossref
Crossref
Richard L. Momparler. (2012) A Perspective on the Comparative Antileukemic Activity of 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza). Pharmaceuticals 5:8, pages 875-881.
Crossref
Crossref
Gillian M. Keating. (2012) Azacitidine. Drugs 72:8, pages 1111-1136.
Crossref
Crossref
Jordan Schecter, Naomi Galili & Azra Raza. (2012) MDS: Refining existing therapy through improved biologic insights. Blood Reviews 26:2, pages 73-80.
Crossref
Crossref
Tapan M. Kadia, Elias Jabbour & Hagop Kantarjian. (2011) Failure of Hypomethylating Agent–Based Therapy in Myelodysplastic Syndromes. Seminars in Oncology 38:5, pages 682-692.
Crossref
Crossref
Thomas PrébetSteven D. GoreBenjamin EsterniClaude GardinRaphael ItzyksonSylvain ThepotFrançois DreyfusOdile Beyne RauzyChristian RecherLionel AdèsBruno QuesnelC.L. BeachPierre FenauxNorbert Vey. (2011) Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. Journal of Clinical Oncology 29:24, pages 3322-3327.
Crossref
Crossref
Sue Ping Lim, Paul Neilsen, Raman Kumar, Andrew Abell & David F. Callen. (2011) The Application of Delivery Systems for DNA Methyltransferase Inhibitors. BioDrugs 25:4, pages 227-242.
Crossref
Crossref
Sagun D Goyal & Amanda Cashen. (2011) Decitabine for the treatment of older patients with myelodysplastic syndrome and acute myelogenous leukemia. Aging Health 7:3, pages 363-378.
Crossref
Crossref
Stefan H. Faderl, Guillermo Garcia-Manero & Hagop M. Kantarjian. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies
103
115
.
Jeffrey J. Molldrem & Gheath Alatrash. (2010) Immune rage against MAGE unleashed. Blood 116:11, pages 1824-1825.
Crossref
Crossref
Katharina Götze, Uwe Platzbecker, Aristoteles Giagounidis, Detlef Haase, Michael Lübbert, Carlo Aul, Arnold Ganser, Ulrich Germing & Wolf-Karsten Hofmann. (2010) Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology 89:9, pages 841-850.
Crossref
Crossref
Alfonso Quintás-Cardama, Fabio P. S. Santos & Guillermo Garcia-Manero. (2010) Therapy with azanucleosides for myelodysplastic syndromes. Nature Reviews Clinical Oncology 7:8, pages 433-444.
Crossref
Crossref
Caterina Musolino, Emanuela Sant’Antonio, Giuseppa Penna, Andrea Alonci, Sabina Russo, Angela Granata & Alessandro Allegra. (2010) Epigenetic therapy in myelodysplastic syndromes. European Journal of Haematology 84:6, pages 463-473.
Crossref
Crossref
Michael Daskalakis, Nadja Blagitko‐Dorfs, Björn Hackanson & Michael Lübbert. (2010) Epigenetische Therapie bei Myelodysplastischen Syndromen (MDS). Therapie mit DNA‐Methyltransferase‐Inhibitoren. Pharmazie in unserer Zeit 39:3, pages 217-227.
Crossref
Crossref
David P. Steensma & Richard M. Stone. (2010) Practical Recommendations for Hypomethylating Agent Therapy of Patients With Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America 24:2, pages 389-406.
Crossref
Crossref
Norbert Gattermann. (2010) How to Treat MDS without Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 16:1, pages S30-S36.
Crossref
Crossref
Michael Daskalakis, Nadja Blagitko-Dorfs & Björn Hackanson. 2010. Small Molecules in Oncology. Small Molecules in Oncology
131
157
.
Lisa Pleyer, Daniel Neureiter, Victoria Faber & Richard Greil. 2010. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes. Chronic Myeloid Neoplasias and Clonal Overlap Syndromes
153
222
.
Gillian M. Keating. (2009) Azacitidine. Drugs 69:17, pages 2501-2518.
Crossref
Crossref
Michael Lübbert. (2009) Epigenetic therapy for myelodysplastic syndromes has entered center stage. Leukemia Research 33, pages S27-S28.
Crossref
Crossref
Isabel Möller, Sabine Blum, Norbert Gattermann, Rainer Haas, Kerstin Habersang, Ulrich Germing & Andrea Kuendgen. (2009) Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine. Annals of Hematology 88:11, pages 1141-1144.
Crossref
Crossref
Michal G. Rose. (2009) Azacitidine improves survival in myelodysplastic syndromes. Nature Reviews Clinical Oncology 6:9, pages 502-503.
Crossref
Crossref
C Flotho, R Claus, C Batz, M Schneider, I Sandrock, S Ihde, C Plass, C M Niemeyer & M Lübbert. (2009) The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23:6, pages 1019-1028.
Crossref
Crossref
Taichun Qin, Jaroslav Jelinek, Jiali Si, Jingmin Shu & Jean-Pierre J. Issa. (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 113:3, pages 659-667.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:4, pages 253-260.
Crossref
Crossref
C. Kurkjian, S. Kummar & A.J. Murgo. (2008) DNA Methylation: Its Role in Cancer Development and Therapy. Current Problems in Cancer 32:5, pages 187-235.
Crossref
Crossref